Provided by Tiger Trade Technology Pte. Ltd.

Lexicon Pharmaceuticals

1.23
-0.0700-5.38%
Volume:1.30M
Turnover:1.64M
Market Cap:446.98M
PE:-6.50
High:1.33
Open:1.31
Low:1.23
Close:1.30
52wk High:1.66
52wk Low:0.2836
Shares:363.40M
Float Shares:183.89M
Volume Ratio:0.87
T/O Rate:0.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1891
EPS(LYR):-0.6262
ROE:-45.92%
ROA:-12.94%
PB:3.72
PE(LYR):-1.96

Loading ...

Lexicon Pharmaceuticals Q3 EPS $(0.04) Beats $(0.07) Estimate, Sales $14.182M Beat $4.649M Estimate

Benzinga
·
Nov 06

BRIEF-Lexicon Pharmaceuticals Q3 EPS USD -0.04

Reuters
·
Nov 06

Lexicon Pharmaceuticals Inc - FDA End-of-Phase 2 Meeting for Pilavapadin in Dpnp by Year-End

THOMSON REUTERS
·
Nov 06

Lexicon Pharmaceuticals Q3 Product Revenue USD 1.008 Million

THOMSON REUTERS
·
Nov 06

Lexicon Pharmaceuticals Inc - Co Has $145 Mln in Cash and Investments as of Sept 30

THOMSON REUTERS
·
Nov 06

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

THOMSON REUTERS
·
Nov 06

Lexicon Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
Nov 04

Lexicon Pharmaceuticals Unveils New Data Highlighting Sotagliflozin’s Unique Benefits in Diverse Patient Populations

Reuters
·
Nov 04

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

GlobeNewswire
·
Oct 30

Lexicon Pharmaceuticals: Promising Phase 2b Results and Strategic Plans Justify Buy Rating

TIPRANKS
·
Oct 14

Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Trials for Diabetic Peripheral Neuropathic Pain Following Positive Phase 2 Data

Reuters
·
Oct 14

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

GlobeNewswire
·
Oct 08

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28%

Simply Wall St.
·
Oct 02

Lexicon Pharmaceuticals Says FDA Delays Feedback on Zynquista Data

MT Newswires Live
·
Sep 23

Lexicon Expects Delay in FDA Feedback on Additional Data for Its Diabetes Drug

Reuters
·
Sep 23

FDA informs Lexicon it requires additional time to review Zynquista NDA

TIPRANKS
·
Sep 23

Lexicon Pharmaceuticals Announces Ongoing FDA Review for Zynquista NDA Resubmission with Additional Data from Multiple Investigator-Sponsored Trials

Reuters
·
Sep 23

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

THOMSON REUTERS
·
Sep 23

Lexicon Pharmaceuticals Inc - FDA Feedback on Zynquista Expected in Q4

THOMSON REUTERS
·
Sep 23

Lexicon Pharmaceuticals: Promising Phase 2b Results for Pilavapadin Support Buy Rating

TIPRANKS
·
Sep 18